ImmunocoreIMCR
About: Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
Employees: 497
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
170% more call options, than puts
Call options by funds: $9.85M | Put options by funds: $3.65M
65% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 34
5.12% more ownership
Funds ownership: 84.3% [Q1] → 89.42% (+5.12%) [Q2]
7% less funds holding
Funds holding: 146 [Q1] → 136 (-10) [Q2]
30% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 33
46% less capital invested
Capital invested by funds: $2.73B [Q1] → $1.48B (-$1.25B) [Q2]
71% less funds holding in top 10
Funds holding in top 10: 7 [Q1] → 2 (-5) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Morgan Stanley Andrew Galler 100% 1-year accuracy 1 / 1 met price target | 128%upside $74 | Overweight Maintained | 11 Oct 2024 |
HC Wainwright & Co. Patrick Trucchio 39% 1-year accuracy 46 / 118 met price target | 208%upside $100 | Buy Reiterated | 17 Sept 2024 |
Needham Gil Blum 42% 1-year accuracy 40 / 95 met price target | 140%upside $78 | Buy Maintained | 17 Sept 2024 |
HC Wainwright & Co. Patrick Trucchio 39% 1-year accuracy 46 / 118 met price target | 208%upside $100 | Buy Reiterated | 28 Aug 2024 |
Oppenheimer Jeff Jones 45% 1-year accuracy 9 / 20 met price target | 174%upside $89 | Outperform Reiterated | 9 Aug 2024 |
